絞り込み

16636

広告

Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.

著者 Kobel C , Frey D , Graf N , Wüthrich RP , Bonani M
Kidney Blood Press Res.2019 Oct 15 ; 44(5):1285-1293.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

Studies in women with post-menopausal osteoporosis have shown that discontinuation of treatment with denosumab leads to an increased risk of vertebral fractures because of rebound bone turnover and rapid loss of bone mineral density (BMD).
PMID: 31614356 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード